Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility

Eli Lilly (NYSE: LLY) will invest more than $3.5 billion to build a new injectable medicine and device manufacturing site in Fogelsville, Lehigh Valley, Pennsylvania, focused on next-generation weight-loss therapies including retatrutide.

Rhea-AI Summary

Eli Lilly (NYSE: LLY) will invest more than $3.5 billion to build a new injectable medicine and device manufacturing site in Fogelsville, Lehigh Valley, Pennsylvania, focused on next-generation weight-loss therapies including retatrutide. The facility is expected to create 850 permanent jobs, 2,000 construction roles, and begin operations in 2031.

The site is Lilly's newest U.S. facility announced since 2020 and part of over $50 billion in capital expansion commitments to expand domestic medicine production.

Positive

• $3.5 billion capital investment in Lehigh Valley
• Creation of 850 high-value permanent manufacturing jobs
• Expected 2,000 construction jobs during buildout
• Facility will produce next-generation therapies including retatrutide
• Adds U.S. manufacturing capacity as part of > $50 billion expansion since 2020

Negative

• Facility not operational until 2031, delaying production capacity
• Construction jobs (2,000) are temporary, not long-term employment guarantees

Argus Jan 30 session

+1.27% close to close Open Argus

Details

News Market Reaction – LLY

On Jan 30, the day this news came out, LLY closed 1.27% above the previous close.

Data tracked by StockTitan Argus for the Jan 30 session.

Market Context

This announcement details a major long-term capacity build, with more than $3.5 billion earmarked fo...

Analysis

This announcement details a major long-term capacity build, with more than $3.5 billion earmarked for a Pennsylvania facility focused on next-generation weight-loss medicines, including retatrutide. It extends over $50 billion of capital expansion commitments since 2020 and adds Lilly’s 10th U.S. manufacturing site. Investors may track progress milestones, construction timing toward the 2031 operational target, and how this site supports broader obesity and metabolic-franchise growth over time.

Key Figures

Lehigh Valley investment: $3.5 billion Total jobs created: 2,800 jobs Permanent high-value jobs: 850 jobs +5 more

Lehigh Valley investment

$3.5 billion

Capital spend for new Pennsylvania injectable medicine facility

Total jobs created

2,800 jobs

Manufacturing and construction jobs tied to Lehigh Valley site

Permanent high-value jobs

850 jobs

Engineers, scientists, operations personnel and lab technicians

Construction jobs

2,000 jobs

Construction phase expected to begin in 2026

Operational target year

2031

Expected start of operations at Lehigh Valley facility

U.S. manufacturing sites

10th site

Lilly’s 10th U.S. manufacturing site announced since 2020

New U.S. sites

Fourth site

Fourth new U.S. manufacturing site announced since February 2025

Capital expansion commitments

$50 billion+

Total capital expansion commitments since 2020

Historical Context

5 past events · Latest: Jan 21

5 events

1. Jan 21

   Earnings call timing

   24h Move

   +3.6%

   Announced date and webcast details for Q4 2025 earnings call.

2. Jan 20

   Regulatory designation

   24h Move

   +0.3%

   FDA Breakthrough Therapy designation for sofetabart mipitecan in ovarian cancer.

3. Jan 09

   Partner IPO link

   24h Move

   -2.0%

   Vida Ventures note on Aktis Oncology IPO and a collaboration valued up to $1.2B.

4. Jan 08

   Clinical trial data

   24h Move

   -2.1%

   Phase 3b TOGETHER-PsA trial showed superior efficacy for Taltz plus Zepbound.

5. Jan 07

   Acquisition deal

   24h Move

   -2.1%

   Agreed all-cash acquisition of Ventyx Biosciences to add NLRP3 pipeline.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

retatrutide, gip, glp-1, glucagon, +4 more

8 terms

retatrutide medical

"develop Lilly's next-generation weight-loss medicines, including retatrutide"

Retatrutide is an investigational prescription medicine being studied to treat obesity and related metabolic conditions by acting on several hormone receptors that control appetite, blood sugar and energy use. For investors, its importance lies in trial results, safety profile and potential approval because successful outcomes could reshape the large market for weight-loss and diabetes therapies, much like a new, more effective tool changing the options on a crowded toolbox.

gip medical

"retatrutide, a first-in-class investigational GIP, GLP-1 and glucagon triple hormone"

GIP commonly stands for Global Infrastructure Partners, a private investment firm that buys and manages large physical assets such as airports, power plants, toll roads and pipelines. Investors pay attention because when GIP acquires, invests in, or sells such assets it can alter cash flow, debt levels and long-term plans for those businesses—like a new landlord changing rents or making upgrades—affecting revenue, dividends and risk for shareholders and creditors.

glp-1 medical

"retatrutide, a first-in-class investigational GIP, GLP-1 and glucagon triple hormone"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

glucagon medical

"investigational GIP, GLP-1 and glucagon triple hormone receptor agonist"

A hormone produced by the pancreas that raises blood sugar by prompting the liver to release stored sugar, acting like the body’s quick energy alarm. For investors, glucagon is important because it is both a key target for diabetes treatments and an approved emergency drug for severe low blood sugar, so changes in clinical data, approvals, manufacturing or demand can affect pharmaceutical and medical-device companies' revenue and valuation.

triple hormone receptor agonist medical

"glucagon triple hormone receptor agonist"

A triple hormone receptor agonist is a drug that simultaneously activates three different hormone ‘switches’ on cells to produce a combined effect, often aimed at treating metabolic conditions like diabetes or obesity. For investors, these drugs can offer greater potential benefit and market differentiation compared with single-target treatments, but they also carry higher development complexity and safety and regulatory risk, which can affect trial outcomes, timelines and valuation.

ai technical

"advanced technologies, including AI, machine learning, integrated monitoring"

Artificial intelligence (AI) is technology that enables machines to mimic human thinking and learning, allowing them to analyze information, recognize patterns, and make decisions. For investors, AI matters because it can improve how businesses operate, create new products, or identify opportunities faster and more accurately than humans alone, potentially impacting company success and market trends.

machine learning technical

"advanced technologies, including AI, machine learning, integrated monitoring"

Machine learning is a set of computer programs that learn patterns from large amounts of data and improve their predictions or decisions over time, like a recipe that gets better each time it’s adjusted based on taste tests. For investors it matters because these systems can speed up analysis, spot trends or risks humans might miss, automate routine work, and potentially create competitive advantages or cost savings that affect a company’s performance.

View in glossary

data analytics technical

"integrated monitoring, and data analytics, to enable efficient operations"

Data analytics is the process of examining large amounts of information to uncover patterns, trends, and insights. It helps investors make better decisions by turning complex data into clear, useful knowledge, much like how a detective finds clues to solve a mystery. This approach enables smarter planning and risk management in financial activities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide

Company plans to create more than 2,800 manufacturing and construction jobs at Lilly's 10^th U.S. manufacturing site announced since 2020

INDIANAPOLIS, Jan. 30, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania. The site will serve as Lilly's newest injectable medicine and device manufacturing facility that will produce next-generation weight-loss therapies, including retatrutide, a first-in-class investigational GIP, GLP-1 and glucagon triple hormone receptor agonist. This is the fourth new U.S. manufacturing site Lilly has announced since February 2025, as part of its commitment to bolster domestic medicine production.  

Lilly will bring 850 high-value jobs to the area, including engineers, scientists, operations personnel and lab technicians. Construction, expected to begin in 2026, is anticipated to generate 2,000 construction jobs. The site will be operational in 2031.

"Our mission starts with patients and delivering the medicines they need. To meet increasing demand, we're expanding our U.S. manufacturing network, with Lehigh Valley adding capacity for next‑generation weight-loss medicines. We're creating high‑quality jobs and collaborating across the region—with suppliers, educators, and workforce‑development partners—to make critical medicines in the U.S.," said David A. Ricks, Lilly chair and CEO. "That's our commitment—to patients, to our new Pennsylvania home and to our country."

Expanding Lilly's U.S. manufacturing presence in Pennsylvania will boost the Lehigh Valley economy. For every dollar Lilly invests, it estimates up to four dollars in additional local economic activity. Also, for each manufacturing job created, several more will be generated in related sectors like supply chain, logistics and retail.

"When we announced our Economic Development Strategy here in the Lehigh Valley two years ago, we set out to win historic, life-changing deals like the one we're announcing with Lilly today," said Governor Josh Shapiro. "Before I took office, Pennsylvania wasn't even in the conversation for major investments like this, but thanks to our work to cut red tape, invest in site development, and expand our workforce, our Commonwealth is now competing—and winning—on a national scale. Lilly's commitment to the Lehigh Valley and to Pennsylvania will bring billions of dollars of investment and hundreds of good-paying jobs, solidifying our position as a leader in the growing life sciences industry." 

The Lehigh Valley site, located in Fogelsville, Pennsylvania, was selected from more than 300 applications, partly based on its proximity to STEM universities, its technical manufacturing economy, and its existing infrastructure. In addition, with increasing demand from the biotech industry, the region offers convenient access to utilities, transportation, and favorable zoning and incentives.

Lilly will utilize advanced technologies, including AI, machine learning, integrated monitoring, and data analytics, to enable efficient operations and a reliable supply of medicine. The company will partner with local universities and invest in education across Pennsylvania to develop talent.

"Lilly Lehigh Valley—our newest injectable medicine and device manufacturing facility—will increase access to next-generation weight-loss treatments and improve the domestic supply of essential medicines for current and future patients," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. "Our investment here is more than just building a facility—it's about building a shared future with the people and communities of the Commonwealth. Through meaningful partnerships in Pennsylvania, we're committed to fostering collaboration, driving innovation, advancing environmental stewardship, and creating lasting positive impact that extends far beyond our facility walls."

This announcement is part of the company's commitment to expand our U.S. manufacturing presence. Since 2020, Lilly's capital expansion commitments total more than $50 billion and include:

• New sites in Alabama, Pennsylvania, Texas, Virginia, North Carolina and Indiana
• Development of the new Lilly Medicine Foundry in Indiana
• Site expansions in Puerto Rico and to our Lilly Technology Center in Indianapolis
• Acquisition and expansion of Lilly's manufacturing site in Wisconsin

Additional Quote Options for Media Use:

U.S. Senator, Dave McCormick: "This multi-billion dollar investment in the Lehigh Valley is a powerful testament to Pennsylvania's leadership in life sciences and advanced manufacturing," said Senator Dave McCormick. "In addition to producing breakthrough medicines and treatments that will improve lives nationwide, Lilly's cutting-edge facility will create thousands of high-quality jobs for working families right here in the Lehigh Valley, proving once again that Pennsylvania's skilled workforce and manufacturing heritage remain unmatched. I am grateful for the continued partnership with the Governor and his team in bringing transformational investments to Pennsylvania. This is American manufacturing at its best, and Pennsylvania is proud to lead the charge."

U.S. Senator, John Fetterman: "Pennsylvania continues to be a leader in health care innovation, and I will always support companies like Lilly making major investments to advance these technologies," said Senator Fetterman. "I am proud to support their new $3.5B manufacturing facility that will deliver hundreds of good jobs and produce critical medicine for our Commonwealth."

Congressman, Ryan Mackenzie: "We are pleased to welcome Eli Lilly to the Lehigh Valley as part of its commitment to investing in America," said Congressman Mackenzie. "Having modern, robust pharmaceutical manufacturing capabilities here in the United States is essential for both our national security and domestic economy. We are proud to see Eli Lilly making this investment here in the Lehigh Valley, where it will contribute to our prosperity and build on our historic manufacturing tradition. Because of the hard work of our local communities, the Lehigh Valley continues to be a hub for industry and investment."

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. C-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements 
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995), including about planned capital investments in new manufacturing capacity, production and delivery of medicines, including retatrutide, hiring and related initiatives and the economic impact thereof and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in the manufacturing process, development and commercialization of pharmaceutical products any of which could impact the overall commercial success of our products, and as related to cost, completion timing, expected capacity, personnel, and other factors which could impact expected benefits of the capacity expansion and related initiatives. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.  

Refer to:	Erica Hiquet; erica.hiquet@lilly.com; 317-739-7498 (Media)
	Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors)

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-selects-pennsylvania-as-home-for-its-newest-injectable-medicine-and-device-manufacturing-facility-302674760.html

SOURCE Eli Lilly and Company

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is Eli Lilly investing in the Lehigh Valley manufacturing facility (LLY)?

The company is investing more than $3.5 billion in the Lehigh Valley site. According to Lilly, the investment will fund a new injectable medicine and device manufacturing facility focused on next-generation weight-loss therapies and associated advanced manufacturing technologies.

How many jobs will Lilly's Lehigh Valley facility create and when will it open?

Lilly expects to create 850 permanent manufacturing roles and about 2,000 construction jobs. According to Lilly, construction is expected to begin in 2026 and the site is anticipated to be operational in 2031.

What medicines will the new LLY Fogelsville site manufacture?

The facility will produce next-generation weight-loss medicines, including retatrutide, a triple hormone receptor agonist. According to Lilly, the site will support injectable medicine and device manufacturing for current and future therapies.

How does the Lehigh Valley project fit into Lilly's broader U.S. manufacturing strategy (LLY)?

This is Lilly's tenth U.S. manufacturing site announced since 2020 and part of > $50 billion in capital commitments. According to Lilly, the project expands domestic capacity and uses advanced technologies like AI and data analytics to secure supply.